Log In
Print this Print this

AERAS-456 (H56IC)

  Manage Alerts
Collapse Summary General Information
Company Aeras Global TB Vaccine Foundation
DescriptionRecombinant subunit vaccine containing TB antigens Ag85B, ESAT6 and Rv2660c combined with the IC31 adjuvant
Molecular Target
Mechanism of Action 
Therapeutic ModalityAdjuvant
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsPrevent active tuberculosis (TB) in patients with latent infections
Regulatory Designation
PartnerStatens Serum Institut;
Valneva SE

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today